Long, Smith, Quinn named to new positions at Roswell Park

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Mary Ann Long
Laurie J. Smith
Timothy Quinn

Three leaders were appointed to Roswell Park Comprehensive Cancer Center:

  • Mary Ann Long was named senior vice president of nursing. Long will focus on evaluating service in inpatient, outpatient and community practices, and will provide leadership to all nursing teams across the center.
    Long was previously director of Magnet at Roswell Park until her retirement in 2012, and also served as assistant director of nursing and director of patient care services, in addition to more than 30 years of service as an intensive care unit nurse.

  • Laurie J. Smith was named vice president of clinical research services. As vice president, Smith will support more than 400 active clinical trials a year and supervise staff engaged in study submission, study implementation, data collection and management.
    Smith previously served as an independent consultant and, prior to that, as vice president of clinical research for AMITA Health in Chicago.
  • Timothy Quinn was named chief of critical care. Quinn, previously co-director of the Intensive Care Unit, has been named to the newly created role of chief of critical care. He will work with members of Roswell Park’s Intensive Care Unit and Intermediate Care Unit to provide cutting-edge and evidence-based oncologic care to patients. A critical care anesthesiologist at the Center, Quinn’s research interests include preoperative evaluation of high-risk patients, intraoperative care and postoperative quality-improvement initiatives.
Table of Contents

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login